Category Archives: Vaccines

Budget cuts threaten HIV vaccine development, say experts

By on .

New HIV infections would decrease by 40 percent within ten years after the launch of an HIV vaccine, experts said at an HIV Vaccine Awareness Day event on Monday hosted by AVAC, IAVI and the Bill and Melinda Gates Foundation. Advancements in technology have paved the way for an effective HIV vaccine, but progress is threatened […]

HIV prevention: on the verge of transformation

By on .

A look at the recent AIDS Vaccine 2012 Conference shows range of prevention developments The following is a guest post from Margaret McGlynn, president and CEO of the International AIDS Vaccine Initiative (IAVI) and William Snow, director of the Global HIV Vaccine Enterprise. More than 1,000 HIV researchers and other professionals involved in HIV prevention […]

Thai trial yield continues with news vaccine changed virus

By on .

The vaccine that showed a vaccine can prevent HIV infection also has shown that the vaccine changed the virus in people who did become infected, according to research revealed today in the first plenary session of AIDS Vaccine 2012. The findings were the third revelation from a study that first generated excitement in the AIDS […]

AIDS Vaccine 2012: Of YECIs and generations of work

By on .

BOSTON, MA — When Bill Snow, now director of the Global HIV Vaccine Enterprise, first became interested in the quest for a vaccine against the AIDS virus, he had a life expectancy of less than 10 years, he said Sunday. That was in 1989, he told the audience gathered for the opening of AIDS Vaccine […]

AIDS Vaccine 2012 will highlight scope of promising prevention advances

By on .

With a completed trial in Thailand that offered evidence a vaccine could be developed to protect people from HIV, emerging science identifying antibodies against HIV, and a current trial testing a novel vaccine combination against the virus potentially producing more information in the next year, this is an exciting time to hold a conference, organizers […]

Dr. Fauci on innovative HIV vaccine initiative awards: “There are fundamental questions that remain unanswered”

By on .

Researchers at 14 institutions will explore new approaches to designing a vaccine against HIV with awards that are part of an anticipated four-year, $34.8 million initiative, the National Institute of Allergy and Infectious Diseases announced today. The awards reflect directions suggested by previous research, as well as the need to explore new avenues toward a […]

NIDA grants $5 million to pursue combo anti-heroin and HIV vaccine

By on .

It sounds like a fantasy, but researchers are making headway in the development of an effective, safe and easily manufactured combination anti-heroin/HIV vaccine. The National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH) has chosen Gary R. Matyas, PhD, to receive the NIDA Avant-Garde Award for Medications Development – a $1 […]

The Final Frontier? NIH reps outline research efforts toward an AIDS cure

By on .

“When they ask me is the glass half empty or half full [in regards to AIDS cure research], I say… we have a glass,” Carl Dieffenbach, PhD, told an audience at the 2012 International AIDS Conference in Washington on Sunday. Dieffenbach, director of the Division of AIDS at the National Institute of Allergy and Infectious […]

Beginning to End the AIDS Epidemic: What’s the Research Agenda?

By on .

Capitol Hill briefing highlights research agenda to end AIDS

The following is a guest blog post by Chris Collins, vice president and director of Public Policy at the Foundation for AIDS Research (amfAR) and Mitchell Warren, executive director of AVAC.

Looking back over three decades of AIDS, it’s hard to point to a better investment than research. Over the past three years, a string of HIV prevention research breakthroughs has put the ambitious goal of even talking about an end of AIDS within sight for the first time. With more strategic use of the tools we have today, we can bend the curve of new infections…

New HIV vaccine trial begins recruiting U.S. participants

By on .

The National Institutes of Health (NIH)-funded HIV Vaccine Trials Network (HVTN) has started enrolling participants in a Phase 1 clinical trial to test a “second-generation” HIV vaccine candidate, meaning the vaccine is identical to the first generation candidate but it includes a special additive to enhance the vaccine response. The additive, or adjuvant, is granulocyte-macrophage […]